Showing results (1121-1130 of 1,351) with videos related to

Sort By:
Pageof 136
Veterinary Microbiology|March 5, 2019
Characterization of mecC gene-carrying coagulase-negative Staphylococcus spp. isolated from various animalsIgor Loncaric, Anna Kübber-Heiss, Annika Posautz, et al.
The Lancet. Oncology|October 12, 2012
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trialGeorgina V Long, Uwe Trefzer, Michael A Davies, et al.
Journal of Cleaner Production|May 29, 2020
LCIA framework and cross-cutting issues guidance within the UNEP-SETAC Life Cycle InitiativeFrancesca Verones, Jane Bare, Cécile Bulle, et al.
The New England Journal of Medicine|June 20, 2024
Final Results for Adjuvant Dabrafenib plus Trametinib in Stage III MelanomaGeorgina V Long, Axel Hauschild, Mario Santinami, et al.
Frontiers in Microbiology|December 27, 2021
Plasmid Mediated <i>mcr-1.1</i> Colistin-Resistance in Clinical Extraintestinal <i>Escherichia coli</i> Strains Isolated in PolandPiotr Majewski, Anna Gutowska, David G E Smith, et al.
The New England Journal of Medicine|January 27, 2012
Neoadjuvant chemotherapy and bevacizumab for HER2-negative breast cancerGunter von Minckwitz, Holger Eidtmann, Mahdi Rezai, et al.
Frontiers in Veterinary Science|August 7, 2025
Temporal changes in fecal swine microbiome primarily reflect <i>Salmonella</i> Typhimurium challenge and poor sanitary housing conditions, even with functional amino acid supplementationAntonio Diego Brandão Melo, Graziela Alves da Cunha Valini, Qinnan Yang, et al.
European Journal of Cancer (Oxford, England : 1990)|February 4, 2025
Diagnosis and treatment of dermatofibrosarcoma protuberans. European interdisciplinary guideline - update 2024Philippe Saiag, Celeste Lebbe, Lieve Brochez, et al.
Future Oncology (London, England)|December 25, 2019
KEYNOTE-716: Phase III study of adjuvant pembrolizumab versus placebo in resected high-risk stage II melanomaJason J Luke, Paolo A Ascierto, Matteo S Carlino, et al.
European Journal of Cancer (Oxford, England : 1990)|May 15, 2017
Open-label, multicentre safety study of vemurafenib in 3219 patients with BRAF<sup>V600</sup> mutation-positive metastatic melanoma: 2-year follow-up data and long-term responders' analysisChristian U Blank, James Larkin, Ana M Arance, et al.
Pageof 136